At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
Lanreotide PRFdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase IIa, Open Label, Dose Ascending Study to Determine the Maximum Tolerated Dose, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Lanreotide PRF in Subjects With Acromegaly Previously Treated and Controlled With Either Octreotide LAR or Lanreotide Autogel
In Brief
A Phase 2 clinical trial evaluating Lanreotide PRF for Acromegaly. Completed, enrolled 28 participants across 36 sites in 12 countries.
Detailed Summary
The objectives of the protocol is to determine the maximum tolerated dose and to investigate the pharmacokinetics of a single dose of lanreotide PRF in subjects with acromegaly.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcromegaly
CountriesBelgium, Czechia, France, Germany, Italy, Lithuania, Netherlands, Poland, Romania, Russia, Spain, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartMar 2015
First PostedMar 2015
Primary CompletionNov 2017
TodayJul 2026
First PostedMar 24, 2015
Enrollment StartMar 1, 2015
Primary CompletionNov 28, 2017
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 11.3 years ago
Interventions
Lanreotide PRFdrug